Amazfit is testing a new blood pressure measurement tool for the Balance smartwatch! This exciting feature, spotted by users in China, Malaysia, and Brazil, brings blood pressure monitoring to your wrist.

Amazfit Testing Blood Pressure Measurement Tool on Balance Smartwatch

While not yet officially announced, the feature seems to be in a limited testing phase. A YouTube video by user @petersoncpxb showcases how it works. Just like with other health metrics on the watch, there’s a dedicated app for blood pressure. Opening the app displays your latest reading with date and time.

Taking a measurement involves tightening the watch band and acknowledging a disclaimer about the watch not being a certified medical device. The process itself takes 30 seconds and requires you to place your arm flat on a table while remaining still. Once finished, the watch displays your systolic and diastolic blood pressure readings, along with your current heart rate. The app also appears to store historical data.

Similar to Samsung’s Galaxy Watch, reports suggest the Amazfit tool might require initial calibration with a traditional blood pressure cuff, with regular sensor recalibration recommended for continued accuracy.

Amazfit unveiled the Balance smartwatch last year in September with extensive health and fitness features powered by AI through Zepp Aura and Zepp Coach. The smartwatch boasts a 1.5-inch AMOLED display, water resistance up to 50m, and a BioTracker for sleep monitoring. It offers meditation and relaxation soundscapes and AI sleep coaching as a paid subscription service. Additionally, it can measure various body metrics and has a battery life of up to 14 days.

The exact date for a wider release of this feature to all Amazfit Balance smartwatches remains unknown. This news is exciting as it suggests Amazfit is pushing the boundaries of smartwatch capabilities, potentially offering a convenient way to monitor blood pressure for users in those select regions. We’ll be keeping an eye on further developments and any official announcements from Amazfit regarding a wider rollout.

In addition to the blood pressure feature being tested, Amazfit recently introduced the Body Composition Analyzer Mat. This companion product to the Balance smartwatch uses bioelectrical impedance analysis to give you a more complete picture of your health by focusing on lower body composition metrics.

RELATED:

• Samsung in a race with Apple to develop needle-free blood sugar monitor
• Zepp OS 3.5 launched with Zepp Flow Natural-Language User Interface
• Get $100 Off on Vivo X100 Pro at Giztop
• Get the Realme GT5 Pro phone on Giztop for $599
• Best of MWC 2024: AI Phone, Transparent Laptop, 3D Tablet & More

(Via)

The post Amazfit quietly testing blood pressure monitoring on its smartwatches appeared first on Gizmochina.

Samsung and Apple are stepping up their game in wearable technology, focusing on developing non-invasive methods for monitoring vital health metrics like blood glucose levels and blood pressure. This new wave of competition is expected to bring significant advancements in health monitoring devices within the next five years.

Samsung and Apple’s Push for Non-Invasive Monitoring Solutions

Apple has also been exploring non-invasive blood glucose monitoring techniques for years. These methods aim to eliminate the need for skin piercing and blood extraction, making the process much easier for patients.

Meanwhile, Huawei has already released a watch last year, the Huawei Watch 4, featuring a non-invasive glucose monitoring capability. This function assesses the risk of high blood sugar by measuring ten health metrics, but it does not directly read blood glucose levels. However, there are uncertainties about the accuracy and functionality of Huawei’s innovation in this area.

Hon Pak, Samsung Mobile’s Head of Digital Health, highlighted in a Bloomberg interview the importance of non-invasive blood glucose monitoring for diabetes patients. He emphasized that wearable devices capable of continuously measuring blood pressure and blood glucose will revolutionize health management. Pak noted that these technologies would be available in some form in the next five years, though no specific timeline was given.

Samsung’s Galaxy Watch already includes blood pressure measurement features, but it requires frequent calibration and doesn’t provide continuous monitoring. The spokesperson also talked about Samsung’s upcoming Galaxy Ring, a wearable device focusing on tracking activity and sleep quality. Over time, it will incorporate more health monitoring features.

This ring is designed for comfort, allowing continuous wear for accurate health data tracking. Its advantage over smartwatches lies in its continuous wearability, as smartwatches often need to be removed for charging, interrupting constant health monitoring.

Moreover, Samsung plans to enhance smart headphones to measure body temperature and heart rate. The company’s vice president explained that the ear is an ideal location for such measurements due to its proximity to the heart. When combined with data from smartwatches, these readings from headphones could offer a more comprehensive view of a user’s health.

RELATED:

• Samsung announces pricing for Galaxy Tab Active 5 rugged tablet
• Samsung’s IAMF 3D audio format set for late 2024 rollout
• Get Redmi K70 Pro for discounted price of $499
• Xiaomi Band 8 Genshin Impact custom edion get a huge discount
• Best of CES 2024 – Products that stood out this year!

(Source)

The post Samsung in a race with Apple to develop needle-free blood sugar monitor appeared first on Gizmochina.

Xiaomi has teased its first-ever smartwatch for blood pressure monitoring. The smartwatch called “Xiaomi Wrist ECG Blood Pressure Recorder” is set to be officially launched on October 26th alongside Xiaomi 14, Hyper OS, and Xiaomi Watch S3.

The Smartwatch will Feature China’s Class II Medical Device Certification

According to the teased image, this smartwatch will feature a round dial with a sleek, non-bulky design and two physical buttons on the right side. The strap seems sturdy and is expected to include inflation and pressure functions to assist in blood pressure measurements. Alongside medical grade features the watch will also incorporate top-tier smart features.

The watch will feature a user-friendly interface that prominently displays blood pressure readings, distinguishing between systolic and diastolic pressures. These readings come with color-coded risk level indicators.

The smartwatch is expected to be highly portable, enabling users to check their blood pressure anywhere, making it especially useful for older individuals managing hypertension. Additionally, it will offer automatic measurement settings for added convenience. The watch has received China’s Class II Medical Device certification.

Additional details from the Beijing Municipal Drug Administration indicate that the Xiaomi Wrist ECG Blood Pressure Recorder package will include the watch, strap, airbag, a charging base, and mobile app software.

It’s important to note that this product is designed for adult use and collects ECG data from the wrist. It utilizes the oscilloscope method to measure blood pressure and pulse, providing values intended for clinical reference. The device is manufactured by Longqi Electronics (Huizhou) Co., Ltd.

RELATED:

• Xiaomi 14 display specifications, color options officially revealed
• Xiaomi launches the MIJIA Wireless Floor Scrubber 2C priced at 999 yuan ($136)
• Alleged Redmi K70 Pro arrives on 3C revealing charging speed
• Samsung Galaxy Tab A9 vs OnePlus Pad Go: Specs Comparison
• What are Software Firewalls And Their Essential Role In Cybersecurity
• Google Pixel 8 vs Google Pixel 8 Pro: Specs Comparison

(Via)

The post Xiaomi to launch its first Blood Pressure Smartwatch with Class II medical device certification on Oct 26 appeared first on Gizmochina.

Earlier this month, the Food and Drug Administration of Guangdong Province released the list of products that it has approved. In this list, the medical grade ECG and blood pressure tracker for a smartwatch from Huawei also received approval.

According to an ITHome report, the Chinese tech giant’s technology making it on the list officially signifies the company’s entry into the field of medical equipments. As per the data from the State Food and Drug Administration, the Huawei smartwatch’s ECG sensor belongs in the second category of medical equipment, with its registration certificate number “20202071705.”

Back in May 2021, He Gang, the president of Huawei’s consumer business smartphone product line, stated that the company’s first smartwatch that supports blood pressure tracking has passed medical device registration tests. Furthermore, the company’s new technology will also start registered clinical trials with professional medical institutions within the next six months. According to the Guangdong Food and Drug Administration, the brand has three other medical devices that have entered the priority approval process.

This includes the wrist ECG blood pressure tracker (MLY-B10, MLY-B11), ECG analysis system (ECG-1), and heart rate disturbance analysis system (PPG-1). While the current generation of smart wearables include a number of health monitoring systems, these are not used for medical diagnoses. Additionally, only a few brands have obtained the second class certificate for medical equipments, namely Huawei, Apple, Huami, and Oppo.

RELATED:

• Huawei’s new Nova series smartphones launching on October 21, Nova 9, Nova 8i expected
• Another report hints at Huawei Mate 50 series launching next year
• Huawei signs agreement with Vodafone to build Europe’s first 5G smart railway port
• Huawei MateBook 14s with 2.5K 90Hz Display set to release globally, starting with UK on October 27

The post Huawei’s medical grade ECG and Blood Pressure Smartwatch approved by China appeared first on Gizmochina.

New York Stock Exchange-listed wearable manufacturer Huami has over the years come out with various innovative features for its smartwatch and fitness bands. The Mi Band manufacturer seems poised to continue to blaze the trail of innovation in the wearable market.

The company is reportedly working on new features that would be introduced to consumers in the near future. Some of the features include ECG and blood pressure monitoring, improvements in AI deep learning, and possible Spotify integration.

This was disclosed in an interview by Zepp Health COO Mike Yeung (via). Zepp is a separate brand under Huami just like the Amazfit brand. The COO hint Huami was currently engaging with the US FDA to get its algorithm certified and also working on areas such as ECG and blood pressure monitoring. He also stated that the company was already in partnership with Alivecor in the US.

Alivcor is a renowned EKG sensor manufacturer and is acclaimed as the first company to get an ECG accessory for the Apple Watch approved by the FDA.

“Everybody heard about how Apple Watch got FDA approval, but to be frank, almost 18 months before that, we actually had our Health Band certified as a medical device by the China FDA so it can measure ECG accurately as a medical device,” Yeung added.

Huami isn’t just trying to get onboard the ECG-packing smartwatch train, instead it is working on a new innovation – cuffless blood pressure monitoring and glucose tracking. “Our biggest achievement is firstly our ECG, and secondly, sleep research. We’re going to continue to refine those further, and then the upcoming is in blood pressure and blood glucose monitoring. We are also quite optimistic now, based on current progress, about glucose monitoring. It’s been a difficult nut to crack, but we are now more optimistic than ever that we can do it,” Yeung disclosed.

In order for its product to appeal to a wider audience in the west, the company is partnering with some prominent brands suchas Spotify, according to Mr Yeung. “We’re with ecosystem partners in some instances, such as Spotify. Music playing and payment, for example, are things we are engaging with all the local partners to beef up. Over half of our products are sold overseas, outside of China. But mostly in Europe and Southeast Asia. We do have a very ambitious plan for North America’s expansion. Actually, we planned to expand very aggressively in North America last year, but due to COVID, we suspended that to resume,” he added.

We can’t say if these new features will be on the upcoming products but we won’t wait for too long to find out.

RELATED;

• Huami to launch third-generation self-developed wearable chip soon
• Huami launches Amazfit Bip U and Bip U Pro smartwatches in the US
• Amazfit T-Rex Pro pricing and hands-on video leaked ahead of launch

The post Amazfit looking to bring ECG and blood pressure monitoring to its wearables appeared first on Gizmochina.

Apple has been actively improving health and fitness-related features for its devices, especially the wearable ones. In line with that, the tech giant has been granted a new patent related to a major blood pressure monitoring system.

Now, a new patent application from Apple, published by the US Patent & Trademark Office reveals a major shift in the company’s blood pressure system. It includes an all-new wearable device, which is separate from Apple Watch.

It seems that instead of a watch interface, the cuff comes with a control unit and the company confirms that the control unit can offer a user interface, including Watch-related functionalities. The product is aimed at estimating the blood pressure value of a patient.

The method covered in this patent includes receiving feature vector data corresponding to a pressure variation of the blood pressure cuff. The data is derived from one or more physiological signals of the patient measured over the pressure variation of the blood pressure cuff.

EDITOR’S PICK: United State’s FCC to take action against Huawei and China Telecom over Security concerns

A first blood pressure value is estimated using the first algorithm with feature vector data as input data. It is then configured to be an estimate of one of the systolic blood pressure of the patient, the diastolic blood pressure of the patient, and the mean arterial blood pressure of the patient.

It is noted that the algorithm is configured to estimate the first blood pressure value of the patient to account for differences between changes in the shape, and/or timing of the one or more physiological signals of the patient measured over the pressure variation of the blood pressure cuff.

UP NEXT: Apple’s ninth-generation iPad launching in Spring 2021 to feature bigger display and better chipset

The post Apple patent application reveals a new wearable blood pressure device appeared first on Gizmochina.

Smartwatches have evolved from being able to track just physical activities to be able to measure other important health data such as your heart rate, your oxygen intake, and your blood pressure. Yesterday, Samsung announced that its Galaxy Watch series will now be able to measure blood pressure. However, users will actually need a sphygmomanometer to calibrate the watch.

The nearly minute-long video released by the official Samsung Newsroom YouTube channel walks users through the process. First, you have to ensure that your watch is tightly fitted to your non-dominant wrist. Then wear the cuff of the blood pressure monitor on the arm of your other hand. Just as you begin measuring with the monitor, your watch also begins to measure your blood pressure automatically.

When the watch is done measuring, you enter the reading from the monitor on your phone. You will be required to take two more measurements before calibration is completed after which you will then be able to use your watch to measure your blood pressure with the watch anytime. The press release advises users to calibrate their watch every four weeks to ensure accuracy.

With the health app on your phone, you will be able to monitor your different blood pressure readings over a period of time as recorded measurements will be synced to the device.

Samsung said the Health Monitor app will be available on the Galaxy Watch Active2 in Q3 2020 and then roll out to upcoming models. So if you own the original Watch Active, you will not be able to make use of this feature.

UP NEXT: Samsung releases Smartwatch App to remind users to Wash their Hands

(Source)

The post Galaxy Watch series gets Blood Pressure monitoring app; needs a sphygmomanometer for calibration appeared first on Gizmochina.

Chinese tech company UMIDIGI has revealed via a tweet posted recently that it will launch a new smartwatch which has as its biggest feature a SpO2 monitor. The smartwatch will be called UMIDIGI UFit and isn’t just a smartwatch but a fitness and health tracker. The product will be launched on March 16.

In the face of the Coronavirus outbreak, the focus on health and fitness has increased. The blood oxygen saturation (SpO2) level is a vital indicator of a person’s health. This tracking the SpO2 level is also a new wearable tech metric getting adopted by more manufacturers. It might sound complicated but SpO2 can reveal conditions. For example, coronavirus and sleep apnea may cause low blood oxygen saturation.

The SpO2 monitor is already in some big-name wearables: Fitbit and Garmin already have an SpO2 sensor on most of their devices, and Huawei has jumped in too. UMIDIGI UFit is expected to also have a SpO2 sensor but it would be much more affordable, in line with UMIDIGI’s market strategy.

There’s still a lot we don’t know about the device, but there are a few things we can speculate from the teaser image. Besides the SpO2 monitoring function, it apparently has a curved screen and 2.5D glass. And there’s a side button to control the watch. We won’t have to wait long to learn more about the smartwatch since it goes official on March 16.

UMIDIGI is also running a giveaway with five units of the UMIDIGI F2 smartphone and fifteen units of the UFit up for takes. You can join the giveaway on their official website. You can also pre-order the UFit on AliExpress.

UP NEXT: Huawei P40 Pro penta-lens camera configuration leaked

The post UMIDIGI UFit smartwatch with SpO2 monitor will be unveiled on March 16 appeared first on Gizmochina.